28.03
-3.44 (-10.93%)
| Previous Close | 31.47 |
| Open | 31.86 |
| Volume | 1,706,819 |
| Avg. Volume (3M) | 426,241 |
| Market Cap | 1,023,036,160 |
| Price / Earnings (TTM) | 23.36 |
| Price / Book | 1.99 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.82 |
| Total Debt/Equity (MRQ) | 2.74% |
| Current Ratio (MRQ) | 31.01 |
| Operating Cash Flow (TTM) | -67.45 M |
| Levered Free Cash Flow (TTM) | -47.00 M |
| Return on Assets (TTM) | -22.89% |
| Return on Equity (TTM) | -33.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Rapport Therapeutics, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 6.28% |
| % Held by Institutions | 105.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Johnson & Johnson | 30 Jun 2025 | 2,498,051 |
| Trv Gp Vi, Llc | 30 Jun 2025 | 969,218 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (HC Wainwright & Co., 21.30%) | Buy |
| Median | 31.00 (10.60%) | |
| Low | 28.00 (JMP Securities, -0.11%) | Buy |
| Average | 31.00 (10.60%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 22.05 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 08 Sep 2025 | 34.00 (21.30%) | Buy | 31.47 |
| 06 Aug 2025 | 31.00 (10.60%) | Buy | 14.61 | |
| JMP Securities | 08 Jul 2025 | 28.00 (-0.11%) | Buy | 12.62 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Sep 2025 | Announcement | Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit |
| 09 Sep 2025 | Announcement | Rapport Announces Pricing of Public Offering of Common Stock |
| 08 Sep 2025 | Announcement | Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures |
| 08 Sep 2025 | Announcement | Rapport Announces Proposed Public Offering of Common Stock |
| 05 Sep 2025 | Announcement | Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 |
| 07 Aug 2025 | Announcement | Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |